Methods and compositions to graft bone using iron excipients

Abstract

A bone graft composition comprising a calcium phosphate putty is provided. A method of repairing a bone defect in a patient by applying the bone graft composition is also provided.

What is claimed is: 
     
         1 . A method of treating a patient having degenerative disc disease, spondylolisthesis, or spinal instability comprising locally administering at a site of vertebral bone disease in the patient a composition comprising a calcium phosphate putty and at least one of the following: a hardening agent, an agent that controls the rate of curing, an acidifying agent, an iron excipient, collagen, and a diluent solution. 
     
     
         2 . The method of  claim 1 , wherein the calcium phosphate putty comprises biphasic calcium phosphate particles. 
     
     
         3 . The method of  claim 2 , wherein the biphasic calcium phosphate particles comprise hydroxyapatite and tricalcium phosphate. 
     
     
         4 . The method of  claim 3 , wherein the biphasic calcium phosphate particles comprise about hydroxyapatite and about 40-80% tricalcium phosphate. The method of  claim 1 , further comprising an active agent. 
     
     
         6 . The method of claim  5 , wherein the active agent is delivered at a controlled rate. 
     
     
         7 . The method of  claim 6 , wherein the active agent is selected from the group consisting of naloxone, naltrexone, and a salt thereof. 
     
     
         8 . The method of  claim 1 , wherein the iron excipient comprises at least one of iron (III) sulfate hydrate, iron (III) chloride, iron (III) citrate, iron (III) oxide, iron (III) hydroxide oxide, iron (III) phosphate, ammonium iron (III) citrate, elemental iron particles, iron (III) fluoride, iron (II) ammonium sulfate hexahydrate, iron (II) chloride, iron (II) disulfide, iron (II) sulfate heptahydrate, iron (II) lactate hydrate, iron (II) L-ascorbate, or iron (II) fluoride. 
     
     
         9 . The method of  claim 1 , wherein the acidifying agent is at least one of ascorbic acid, magnesium citrate, potassium citrate, sodium citrate, citric acid monohydrate, and acetic acid. The method of  claim 1 , wherein the hardening agent is at least one of sodium carbonate, calcium sulfate anhydrate, calcium sulfate hemihydrate, calcium sulfate dihydrate, calcium carbonate, magnesium carbonate, strontium carbonate, and bioglass. 
     
     
         11 . The method of  claim 1 , wherein the agent that controls the rate of curing is at least one of calcium oxide, magnesium oxide, sodium phosphate dibasic, sodium pyrophosphate tetrabasic, sodium orthophosphate, or sodium phosphate monobasic. 
     
     
         12 . The method of  claim 1 , wherein the patient has degenerative disc disease. 
     
     
         13 . The method of  claim 1 , wherein the patient has spondylolisthesis. 
     
     
         14 . The method of  claim 1 , wherein the patient has spinal instability. The method of  claim 1 , wherein the patient further has at least one of disc degeneration, disc herniation, decreased disc height, osteophyte formation, ligamentous thickening, facet joint degeneration, foraminal narrowing, or loss of foraminal height. 
     
     
         16 . The method of  claim 1 , wherein X-radiographs of the patient during flexion/extension movement show angulation≥5 degrees and/or translation≥4 mm of the affected vertebral bone(s).